ARTICLE | Clinical News
Lantus insulin glargine: Phase III started
November 19, 2012 8:00 AM UTC
Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lantus insulin glargine Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Synthetic sustained-release subcu...